| High expression viral vectors for hemophilia A gene therapy encoding … |
2023-6-30 |
2023-8-18 |
|
| Boronate ester compounds and pharmaceutical compositions thereof |
2023-5-03 |
2023-8-24 |
|
| Nucleic acid-containing lipid nanoparticles and uses thereof |
2023-4-28 |
2023-7-11 |
|
| Adeno-associated virus purification method |
2023-4-26 |
2023-6-27 |
|
| Recombinant human C1 esterase inhibitor and use thereof |
2023-4-21 |
2023-6-15 |
|
| Constrained, Conditionally Activated Binding Proteins |
2023-4-20 |
2023-7-04 |
|
| Methods of purifying recombinant adamts13 and other proteins and compositions … |
2023-4-11 |
2023-8-03 |
|
| Capsule and powder formulations containing lanthanum compounds |
2023-3-28 |
2023-5-25 |
|
| Heterocyclic compounds and uses thereof |
2023-3-27 |
2023-6-06 |
|
| Combination therapy for cancer treatment |
2023-3-16 |
2023-6-29 |
|
| Thienopyrimidine derivatives and production methods thereof |
2023-3-15 |
2023-7-06 |
|
| Modification-dependent activity assay |
2023-3-08 |
2023-6-13 |
|
| Bispecific antibodies against plasma kallikrein and factor xii |
2023-3-07 |
2023-5-12 |
|
| Subcutaneous administration of ADAMTS13 |
2023-3-01 |
2023-5-23 |
|
| Treatment of prostate cancer |
2023-2-22 |
2023-3-23 |
|
| Novel t-cell receptor |
2023-2-06 |
2023-8-17 |
|
| Pooling device for single or multiple containers |
2023-2-03 |
2023-3-09 |
|
| Adeno-associated virus formulations |
2023-1-13 |
2023-8-03 |
|
| Heteroaryl compounds for kinase inhibition |
2023-1-13 |
2023-4-11 |
|
| Compositions and methods for treatment of diabetic macular edema |
2023-1-11 |
2023-3-03 |
|
| Stabilized liquid and lyophilized adamts13 formulations |
2022-12-23 |
2023-4-27 |
|
| Liquid preparations of amines and organic acids stabilized by salts |
2022-12-16 |
2023-5-11 |
|
| C1 esterase inhibitor fusion proteins and use thereof |
2022-12-15 |
2023-3-01 |
|
| Treatment of CNS conditions |
2022-12-14 |
2023-3-01 |
|
| Di-aliphatic substituted pegylated lipids |
2022-11-10 |
2023-2-02 |
|
| GIP receptor activating peptide |
2022-11-09 |
2023-1-25 |
|
| Plasma kallikrein-binding protein in treatment of hereditary angioedema and use … |
2022-10-20 |
2023-1-31 |
|
| Methods of treating antibody-mediated rejection in organ transplant patients … |
2022-10-11 |
2022-12-02 |
|
| Sulfonyl piperidine derivatives and their use for treating prokineticin … |
2022-10-10 |
2023-3-09 |
|
| Process for producing pyrrole compound |
2022-10-07 |
2023-3-23 |
|
| Diagnosis and treatment for autoimmune disease |
2022-10-06 |
2022-12-27 |
|
| Methods of treating uterine fibroids and endometriosis |
2022-9-30 |
2022-10-27 |
|
| Plasma kallikrein binding protein |
2022-9-21 |
2022-12-20 |
|
| A method to produce a highly concentrated immunoglobulin preparation for … |
2022-9-07 |
2022-9-29 |
|
| Benzoxazole kinase inhibitors and methods of use |
2022-9-01 |
2022-11-09 |
|
| Anti-cd38 antibodies |
2022-8-31 |
2023-2-09 |
|
| Assays for determining plasma kallikrein system biomarkers |
2022-8-31 |
2022-12-20 |
|
| Methods for purification of arylsulfatase a |
2022-8-25 |
2022-9-22 |
|
| Nitrogen-containing heterocyclic compound |
2022-7-25 |
2022-12-29 |
|
| Heterocyclic compound and use thereof |
2022-6-22 |
2023-3-02 |
|
| Plasma kallikrein binding proteins |
2022-6-17 |
2023-4-13 |
|
| Use of ADAMTS13 to treat, ameliorate and/or prevent vaso-occlusive crisis, … |
2022-6-16 |
2023-1-13 |
2023-1-13 |
| Fused heteroaromatic pyrrolidinones as SYK inhibitors |
2022-5-20 |
2022-7-28 |
|
| Inducible binding proteins and methods of use thereof |
2022-5-18 |
2022-9-28 |
|
| Plasma kallikrein inhibitors and uses thereof for treating hereditary … |
2022-5-16 |
2023-4-06 |
|
| Phosphorus derivatives as kinase inhibitors |
2022-5-13 |
2022-8-09 |
|
| Plasma kallikrein inhibitors and uses thereof for preventing hereditary … |
2022-5-12 |
2022-6-02 |
|
| Antibody against fcrn and use thereof |
2022-5-02 |
2022-8-09 |
|
| Antibody drug conjugates |
2022-4-27 |
2022-8-11 |
|
| Inhibitors of plasma kallikrein and uses thereof |
2022-4-20 |
2023-3-16 |
|
| Method for providing therapeutic plasma protein administration plan, and … |
2022-4-11 |
2022-7-12 |
|
| Anti-plasma kallikrein antibodies |
2022-4-10 |
2022-6-01 |
|
| Alginate hydrogel compositions |
2022-4-01 |
2022-5-26 |
|
| EVALUATION, ASSAY, AND TREATMENT OF pKal-ASSOCIATED DISEASE |
2022-3-31 |
2022-7-20 |
|
| 2-Isoindole-1,3,4-oxadiazole derivatives useful as histone deacetylase 6 (hdac6 … |
2022-3-25 |
2023-1-20 |
|
| Small unit dosage plunger rod stops |
2022-3-09 |
2022-5-24 |
|
| Treatment of Coagulation Disease by Administration of Recombinant VWF |
2022-3-04 |
2022-3-24 |
|
| Evaluation and treatment of bradykinin-mediated disorders |
2022-2-28 |
2022-6-07 |
|
| Formulation for anti-alpha4beta7 antibody |
2022-2-22 |
2022-11-24 |
|
| Plasma kallikrein inhibitors and uses thereof for treating hereditary … |
2022-2-16 |
2022-10-06 |
|
| Adipose tissue-derived stromal stem cells for use in treating refractory … |
2022-2-14 |
2022-8-11 |
|
| Methods and compositions for cns delivery of iduronate-2-sulfatase |
2022-1-18 |
2023-1-26 |
|
| Modular vial adapter |
2022-1-07 |
2022-3-25 |
|
| Method of Producing Recombinant ADAMTS13 in Cell Culture |
2022-1-05 |
2022-1-20 |
|
| Relugolix or a salt thereof |
2021-12-31 |
2022-5-25 |
|
| Nucleophilic catalyst for oxime ligation |
2021-12-29 |
2023-7-06 |
2023-7-06 |
| Lyophilized recombinant VWF preparation |
2021-12-28 |
2022-3-08 |
|
| Nucleophilic catalysts for oxime linkage |
2021-12-27 |
2022-3-23 |
|
| Optimized binuclease fusions and methods |
2021-12-23 |
2022-4-14 |
|
| Removal of serine proteases by treatment with finely divided silicon dioxide |
2021-12-16 |
2022-1-20 |
|
| Heterocyclic compound |
2021-12-14 |
2023-8-01 |
2023-8-01 |
| Method and apparatus for providing a pharmacokinetic drug dosing regimen |
2021-12-08 |
2022-2-01 |
|
| Inhibitors of plasma kallikrein and uses thereof |
2021-11-04 |
2022-2-24 |
|
| Solid state forms of fused heteroaromatic pyrrolidinones |
2021-11-04 |
2022-1-25 |
|
| A composition comprising a polypeptide |
2021-10-29 |
2008-10-31 |
|
| Prophylactic or therapeutic agent for delirium |
2021-10-07 |
2022-3-31 |
|
| Adamts13-containing compositions having thrombolytic activity |
2021-9-17 |
2022-1-06 |
|
| UTI fusion proteins |
2021-8-31 |
2021-9-30 |
|
| Pyridazinone compounds and their use as daao inhibitors |
2021-8-30 |
2022-1-13 |
|
| Heterocyclic compound |
2021-7-02 |
2022-1-25 |
2022-1-25 |
| Method for producing pyrrole compound |
2021-6-17 |
2021-10-07 |
|
| Recombinant viral vectors and nucleic acids for producing the same |
2021-5-21 |
2021-10-21 |
|
| Monoclonal antibody inhibitors of factor XIIa |
2021-5-19 |
2023-7-31 |
2023-7-31 |
| Piperidinyl-3-(aryloxy)propanamides and propanoates |
2021-5-14 |
2023-1-26 |
|
| Amide compound |
2021-5-10 |
2021-9-09 |
|
| Cyclic dinucleotides as sting (stimulator of inteferon genes) agonists |
2021-5-10 |
2021-10-01 |
|
| Cell culture medium for ADAMTS protein expression |
2021-5-07 |
2022-6-09 |
2022-6-09 |
| Method for the activation and proliferation of t cells |
2021-4-21 |
2021-4-30 |
|
| Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g |
2021-4-19 |
2021-8-05 |
|
| Adeno-associated virus purification methods |
2021-4-12 |
2021-11-04 |
|
| Heterocyclic compound |
2021-4-09 |
2021-11-04 |
|
| Antibodies which bind Fc receptors (FcRn) |
2021-3-17 |
2023-8-29 |
2023-8-29 |
| Heterocyclic compound and use thereof |
2021-3-15 |
2023-7-18 |
2023-7-18 |
| Methods for cancer therapy |
2021-3-01 |
2022-2-08 |
2022-2-08 |
| Methods for producing natural killer cells from pluripotent stem cells |
2021-2-26 |
2022-11-04 |
|
| Cyclopropanamine compound and use thereof |
2021-2-16 |
2021-6-17 |
|
| Nucleophilic catalysts for oxime linkage |
2021-2-05 |
2021-6-03 |
|
| Method for the production of gamma delta t cells |
2021-1-29 |
2021-2-08 |
|
| Substituted piperidine compound and use thereof |
2021-1-21 |
2022-3-17 |
|
| Immunoassay to detect cleaved high molecular weight kininogen |
2021-1-05 |
2021-9-02 |
|